I disagree. There's a difference between the first

I disagree. There's a difference between the first NEW CLASS of antibiotics since 1987, and an antibiotic -- no matter how much of a blockbuster it might be -- that is similar to others.

Here's what Cubist bought when it acquired Trius:

Quote:

---

With the purchases, Cubist gets Dificid, approved to combat a diarrhea-causing infection commonly acquired in hospitals, and Trius’s tedizolid phosphate, a medicine in late-stage trials intended to treat staph infections resistant to the common antibiotic methicillin. Dificid gained FDA approval in May 2011 as the first new antibiotic approved in 25 years for treatment of infections by the bacteria clostridium difficile. Optimer reported 2012 sales of $62.4 million for the drug.

http://www.bloomberg.com/news/articles/2013-0...ital-drugs

---

Do you really think that is equivalent to Brilacidin? I don't. Dificid has NOT solved the c. difficile problem, and is methicillin-resistant infection now easily curable because of Cubist's drug? Do you really think Brilacidin's sales would be only 62 million, if it really does cure these terrible infections in one dose?
Just because someone said that the Trius/Cubist deal is what Brilacidin should be valued at, doesn't make it so.